Título Abreviado: ECM 22/1848 ZUMA-23
Investigador Principal: Alejandro Martín García Sancho
Código EUDRACT:
Código Identificativo: ECI2022/0158

KT-US-484-0136

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)

Estado: ACTIVO

Pin It en Pinterest